BRPI0914969A2 - método para diagnóstico de cânceres que expressam o receptor de her2 ou suas variantes truncadas - Google Patents

método para diagnóstico de cânceres que expressam o receptor de her2 ou suas variantes truncadas

Info

Publication number
BRPI0914969A2
BRPI0914969A2 BRPI0914969A BRPI0914969A BRPI0914969A2 BR PI0914969 A2 BRPI0914969 A2 BR PI0914969A2 BR PI0914969 A BRPI0914969 A BR PI0914969A BR PI0914969 A BRPI0914969 A BR PI0914969A BR PI0914969 A2 BRPI0914969 A2 BR PI0914969A2
Authority
BR
Brazil
Prior art keywords
her2 receptor
cancers expressing
truncated variants
diagnosing cancers
diagnosing
Prior art date
Application number
BRPI0914969A
Other languages
English (en)
Inventor
Joaquín Arribas López
Josep Lluis Parra Palau
José Baselga Torres
Kim Pedersen
Pier-Davide Angellini
Sirle Laos
Original Assignee
Fundació Privada Institució Catalana De Recerca I Estudis Avancats
Fundació Privada Inst D Investigació Oncológica De Vall Hebron
Fundació Privada Inst De Recerca Hospital Uni Vall Hebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundació Privada Institució Catalana De Recerca I Estudis Avancats, Fundació Privada Inst D Investigació Oncológica De Vall Hebron, Fundació Privada Inst De Recerca Hospital Uni Vall Hebron filed Critical Fundació Privada Institució Catalana De Recerca I Estudis Avancats
Publication of BRPI0914969A2 publication Critical patent/BRPI0914969A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0914969A 2008-06-02 2009-06-05 método para diagnóstico de cânceres que expressam o receptor de her2 ou suas variantes truncadas BRPI0914969A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200801652A ES2342646B1 (es) 2008-06-02 2008-06-02 Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
PCT/EP2009/056976 WO2010000565A1 (en) 2008-06-02 2009-06-05 Method for diagnosing cancers expressing the her2 receptor or its truncated variants

Publications (1)

Publication Number Publication Date
BRPI0914969A2 true BRPI0914969A2 (pt) 2015-10-20

Family

ID=40911029

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914969A BRPI0914969A2 (pt) 2008-06-02 2009-06-05 método para diagnóstico de cânceres que expressam o receptor de her2 ou suas variantes truncadas

Country Status (20)

Country Link
US (1) US8389227B2 (pt)
EP (1) EP2293819B1 (pt)
JP (2) JP5753079B2 (pt)
KR (2) KR20160140974A (pt)
CN (1) CN102202692B (pt)
AU (2) AU2009265921B2 (pt)
BR (1) BRPI0914969A2 (pt)
CA (1) CA2727365A1 (pt)
CY (1) CY1115798T1 (pt)
DK (1) DK2293819T3 (pt)
EA (1) EA025218B1 (pt)
ES (2) ES2342646B1 (pt)
HR (1) HRP20141158T1 (pt)
IL (1) IL209769A (pt)
MX (1) MX2010013419A (pt)
PL (1) PL2293819T3 (pt)
PT (1) PT2293819E (pt)
SI (1) SI2293819T1 (pt)
WO (1) WO2010000565A1 (pt)
ZA (1) ZA201009010B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081649A2 (en) * 2001-04-06 2002-10-17 The Trustees Of The University Of Pennsylvania ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
EP2235536A4 (en) 2007-12-20 2011-05-04 Lab Corp America Holdings HER-2-DIAGNOSTIC PROCEDURE
ES2342646B1 (es) * 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
ES2637411T3 (es) 2008-12-01 2017-10-13 Laboratory Corporation Of America Holdings Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95
EP2387711B1 (en) 2009-01-15 2015-04-22 Laboratory Corporation of America Holdings Methods of determining patient response by measurement of her-3
NZ596468A (en) * 2009-05-14 2013-11-29 Nestec Sa Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
PT2330131E (pt) * 2009-12-07 2015-01-14 Fundació Privada Institució Catalana De Recerca I Estudis Avancats Anticorpos contra a variante truncada de her-2 ctf-611
CN103102414B (zh) * 2013-02-04 2014-08-27 无锡傲锐东源生物科技有限公司 抗her2蛋白单克隆抗体及其用途
US20160067307A1 (en) 2013-05-01 2016-03-10 Five Prime Therapeutics, Inc. Methods of treating cancer
ES2809729T3 (es) 2014-03-11 2021-03-05 Molecular Templates Inc Proteínas que comprenden regiones efectoras de la subunidad A de la toxina Shiga próximas al extremo amino terminal y regiones de unión de tipo inmunoglobulina de reconocimiento celular capaces de unirse específicamente a HER2/neu/ErbB2
JP6935195B2 (ja) 2014-03-11 2021-09-15 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
EP3303373B1 (en) 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
KR20180030085A (ko) 2015-07-26 2018-03-21 몰레큘러 템플레이츠, 인코퍼레이션. 시가 독소 a 서브유닛 작동체 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
CN109476744B (zh) * 2016-05-12 2023-04-11 新加坡科技研究局 抗erbb-2抗体及其用途
US10882918B2 (en) 2016-09-30 2021-01-05 Hoffmann-La Roche Inc. Bispecific T cell activating antigen binding molecules
MX2019008840A (es) 2017-01-25 2019-09-09 Molecular Templates Inc Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+.
CN110612117B (zh) 2018-04-17 2024-04-12 分子模板公司 包含去免疫化的志贺毒素a亚基支架的her2靶向分子
CN110172448B (zh) * 2019-05-30 2020-07-28 中南大学湘雅二医院 一种滑膜肉瘤细胞系hSS-005R及其子代细胞系
BR112022001148A2 (pt) 2019-07-23 2022-03-15 Inst Nat Sante Rech Med Células imunes modificadas, composição farmacêutica, kit, uso de uma célula imune modificada e invenção de produto
CN110865184B (zh) * 2019-12-04 2023-04-07 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） Srsp蛋白和srsp抗原表位肽的应用及诊断和治疗肿瘤的产品
EP4077368A1 (en) * 2019-12-18 2022-10-26 Bracco Imaging SPA Anti-her2 polypeptides derivatives as new diagnostic molecular probes
EP3915576A1 (en) 2020-05-28 2021-12-01 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Chimeric antigen receptors specific for p95her2 and uses thereof
JP2025501272A (ja) 2021-12-28 2025-01-17 ムネモ・セラピューティクス 不活性化されたｓｕｖ３９ｈ１及び改変ｔｃｒを有する免疫細胞
EP4253418A1 (en) 2022-03-29 2023-10-04 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof
EP4279085A1 (en) 2022-05-20 2023-11-22 Mnemo Therapeutics Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene
KR20250147080A (ko) * 2024-04-03 2025-10-13 한국원자력의학원 방사성동위원소가 표지된 항-her2 항체-킬레이터 접합체, 이를 포함하는 약학적 조성물 및 이의 제조방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
DE69535673D1 (de) 1994-08-30 2008-02-07 Univ Dundee Mittel zur induktion von apoptosis und zur therapieanwendung
DE69725857T2 (de) * 1996-08-14 2004-07-29 The Government of the United States of America, as represented by the Secretary National Institute of Health, Office of Technology Transfer Vektor für polynukleotidimpfstoffe
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
DE60040981D1 (de) 1999-05-14 2009-01-15 Genentech Inc BEHANDLUNG MIT ANTI-ErbB2 ANTIKÖRPERN
KR20110008112A (ko) * 1999-08-27 2011-01-25 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
EP1653986A4 (en) * 2003-08-01 2007-03-14 Smithkline Beecham Corp TREATMENT OF P95 ERBB2 EXPRESSIVE CARCINOMA
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
ES2342646B1 (es) * 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
ES2637411T3 (es) * 2008-12-01 2017-10-13 Laboratory Corporation Of America Holdings Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95

Also Published As

Publication number Publication date
ZA201009010B (en) 2012-03-28
JP5753079B2 (ja) 2015-07-22
ES2528132T3 (es) 2015-02-04
PL2293819T3 (pl) 2015-04-30
ES2342646B1 (es) 2011-04-26
ES2342646A1 (es) 2010-07-09
EP2293819A1 (en) 2011-03-16
KR20160140974A (ko) 2016-12-07
EA201001874A1 (ru) 2011-08-30
KR20110031187A (ko) 2011-03-24
KR101785117B1 (ko) 2017-11-07
HK1157658A1 (en) 2012-07-06
HRP20141158T1 (hr) 2015-02-13
WO2010000565A1 (en) 2010-01-07
IL209769A0 (en) 2011-02-28
CN102202692B (zh) 2014-03-12
JP2015214546A (ja) 2015-12-03
AU2015202854A1 (en) 2015-06-18
US20090311262A1 (en) 2009-12-17
CA2727365A1 (en) 2010-01-07
DK2293819T3 (en) 2014-12-08
IL209769A (en) 2016-04-21
EP2293819B1 (en) 2014-09-03
CN102202692A (zh) 2011-09-28
MX2010013419A (es) 2011-08-15
JP2011525175A (ja) 2011-09-15
PT2293819E (pt) 2014-12-09
EA025218B1 (ru) 2016-12-30
US8389227B2 (en) 2013-03-05
CY1115798T1 (el) 2017-01-25
SI2293819T1 (sl) 2015-01-30
AU2009265921B2 (en) 2015-04-02
AU2009265921A1 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
BRPI0914969A2 (pt) método para diagnóstico de cânceres que expressam o receptor de her2 ou suas variantes truncadas
HRP20250807T8 (hr) Protutijela koja vežu ljudski cgrp receptor
BRPI0916366A2 (pt) exame diagnóstico de anticorpo
BRPI0923199A2 (pt) métodos e composições para detecção de anticorpos com fixação de complemento.
BRPI0919256A2 (pt) sistema de diagnóstico de integridade de riser submarino
FR2923957B1 (fr) Unite formant coque de blindage
PT2170959E (pt) Anticorpos para o receptor humano de morte programada pd-1
EP2256523A4 (en) SENSOR FOR AUTOMATIC DOOR
EP2300828A4 (en) SCREENING SYSTEM FOR ANTIGENS
BRPI0813569A2 (pt) Método de inspeção.
BRPI0906491A2 (pt) Método para reconstrução de imagem.
BRPI0906931A2 (pt) Unidade de embalagem para artigos com recursos de abertura
BRPI0816624A2 (pt) Sapata de trilho ferroviário
EP2372982A4 (en) GLEITSCHARNIERMECHANISMUS
BRPI0921151A2 (pt) técnica para padronização de conteúdo
PT2214358T (pt) Método para o mapeamento de túneis
BRPI0812465A2 (pt) Expressão de fragmento de anticorpo solúvel por truncação de domínio ch1
BRPI0810566A2 (pt) métodos de ativação de transponder
BRPI0914972A2 (pt) instalação de estacionamento para veículos automóveis
FR2922011B1 (fr) Instrument de secours pour aeronef.
ES1062269Y (es) Remolque de arrastre para trabajos de la vendimia
ES1065327Y (es) Dispositivo para la union de barandas
ES1069558Y (es) Dispositivo empotrable para la sujecion de elementos de seguridad
ES1062134Y (es) Dispositivo de union para cubitera.
FR2912510B1 (fr) Installation de test.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 16/32 (2006.01), G01N 33/574 (2006.01)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements